Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice
Armin Rehm, … , Gerald Willimsky, Uta E. Höpken
Armin Rehm, … , Gerald Willimsky, Uta E. Höpken
Published April 28, 2022
Citation Information: JCI Insight. 2022;7(11):e155534. https://doi.org/10.1172/jci.insight.155534.
View: Text | PDF
Research Article Immunology Oncology

EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice

  • Text
  • PDF
Abstract

Insight into processes that determine CD8+ T cell memory formation has been obtained from infection models. These models are biased toward an inflammatory milieu and often use high-avidity CD8+ T cells in adoptive-transfer procedures. It is unclear whether these conditions mimic the differentiation processes of an endogenous repertoire that proceed upon noninflammatory conditions prevailing in premalignant tumor lesions. We examined the role of cytolytic capacity on CD8+ T cell fate decisions when primed by tumor cells or by minor histocompatibility antigen–mismatched leukocytes. CD8+ memory commitment was analyzed in Ebag9-deficient mice that exhibited enhanced tumor cell lysis. This property endowed Ebag9–/– mice with extended control of Tcl-1 oncogene–induced chronic lymphocytic leukemia progression. In Ebag9–/– mice, an expanded memory population was obtained for anti-HY and anti–SV-40 T antigen–specific T cells, despite unchanged effector frequencies in the primary response. By comparing the single-cell transcriptomes of CD8+ T cells responding to tumor cell vaccination, we found differential distribution of subpopulations between Ebag9+/+ and Ebag9–/– T cells. In Ebag9–/– cells, these larger clusters contained genes encoding transcription factors regulating memory cell differentiation and anti-apoptotic gene functions. Our findings link EBAG9-controlled cytolytic activity and the commitment to the CD8+ memory lineage.

Authors

Armin Rehm, Anthea Wirges, Dana Hoser, Cornelius Fischer, Stefanie Herda, Kerstin Gerlach, Sascha Sauer, Gerald Willimsky, Uta E. Höpken

×

Figure 5

Immunization with the strong TAg-neoantigen under noninflammatory conditions induces a higher CD8+ T cell memory response in Ebag9–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
Immunization with the strong TAg-neoantigen under noninflammatory condit...
(A) WT (+/+) and Ebag9–/– (–/–) mice were immunized i.p. with 1 × 106 TAg+ 16.113 tumor cells. At day 6, splenic CD8+ T lymphocytes reactive to the immunodominant peptide IV antigen were detected with a Kb/IV Tetramer (Tet IV). A representative dot plot shows an antigen-specific CD8+Tet IV+ population is gated. (Right) CD44 expression indicates activation; n = 2 independent experiments. (B) In the effector phase, WT and Ebag9–/– show similar frequencies of TAg-specific CD8+ T cells. Frequencies of CD8+/Tet IV+ T cells among all splenocytes are shown. Student’s t test was applied; WT mice, n = 6–12; KO mice, n = 6–11. (C) Increased frequencies and numbers of Tet IV-reactive CD8+CD44hi T cells in Ebag9–/– mice. WT and Ebag9–/– mice were immunized as in A; 55–65 days later, splenocytes were stained without in vitro restimulation with anti-CD8, anti-CD44, and Tet IV tetramers. Frequencies are reported as percentages of CD8+Tet IV+CD44hi T cells among all splenocytes. (D) Total numbers of CD8+Tet IV+CD44hi T cells within spleens. Bars indicate mean values; n = 3 independent experiments, with 10 WT and 11 KO mice. Student’s t test was applied. (E) Distinction between TCM and TEM cells made by CD44+CD62Llo (EM) or CD44+ CD62Lhi (CM) co-staining. Bar graph indicates the frequency, in percentages, of TEM and TCM among all CD8+CD44hi TetIV-specific T cells. (F and G) Representative dot plots show the gating strategy for TAg-specific (Tet IV) CD8+ T cell detection and distinction into TCM and TEM cells. Numbers in the gates are the percentages of antigen-specific T cells, TCM, and TEM cells.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts